Search Results - "Ricciuti, Biagio"

Exclusion of patients living with HIV from cancer immune checkpoint inhibitor trials by Vora, Kruti B., Ricciuti, Biagio, Awad, Mark M.

“…Emerging retrospective and prospective studies indicate that immune checkpoint inhibitors (ICIs) can be safe and effective cancer treatments among people…”
Get full text

Association between Smoking History and Tumor Mutation Burden in Advanced Non-Small Cell Lung Cancer by Wang, Xinan, Ricciuti, Biagio, Nguyen, Tom, Li, Xihao, Rabin, Michael S, Awad, Mark M, Lin, Xihong, Johnson, Bruce E, Christiani, David C

“…Lung carcinogenesis is a complex and stepwise process involving accumulation of genetic mutations in signaling and oncogenic pathways via interactions with…”
Get full text

Endothelial and cardiac progenitor cells for cardiovascular repair: A controversial paradigm in cell therapy by Bianconi, Vanessa, Sahebkar, Amirhossein, Kovanen, Petri, Bagaglia, Francesco, Ricciuti, Biagio, Calabrò, Paolo, Patti, Giuseppe, Pirro, Matteo

“…Stem cells have the potential to differentiate into cardiovascular cell lineages and to stimulate tissue regeneration in a paracrine/autocrine manner; thus,…”
Get full text

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status by Ricciuti, Biagio, Arbour, Kathryn C, Lin, Jessica J, Vajdi, Amir, Vokes, Natalie, Hong, Lingzhi, Zhang, Jianjun, Tolstorukov, Michael Y, Li, Yvonne Y, Spurr, Liam F, Cherniack, Andrew D, Recondo, Gonzalo, Lamberti, Giuseppe, Wang, Xinan, Venkatraman, Deepti, Alessi, Joao V, Vaz, Victor R, Rizvi, Hira, Egger, Jacklynn, Plodkowski, Andrew J, Khosrowjerdi, Sara, Digumarthy, Subba, Park, Hyesun, Vaz, Nuno, Nishino, Mizuki, Sholl, Lynette M, Barbie, David, Altan, Mehmet, Heymach, John V, Skoulidis, Ferdinandos, Gainor, Justin F, Hellmann, Matthew D, Awad, Mark M

“…STK11 and KEAP1 mutations (STK11 mutant [STK11 ] and KEAP1 ) are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11 has been…”
Get more information

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis by Abu-Sbeih, Hamzah, Ali, Faisal S, Naqash, Abdul Rafeh, Owen, Dwight H, Patel, Sandipkumar, Otterson, Gregory A, Kendra, Kari, Ricciuti, Biagio, Chiari, Rita, De Giglio, Andrea, Sleiman, Joseph, Funchain, Pauline, Wills, Beatriz, Zhang, Jiajia, Naidoo, Jarushka, Philpott, Jessica, Gao, Jianjun, Subudhi, Sumit K, Wang, Yinghong

“…Immune checkpoint inhibitor (ICI) therapy often is suspended because of immune-mediated diarrhea and colitis (IMDC). We examined the rate of and risk factors…”
Get full text

Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer by Ricciuti, Biagio, Recondo, Gonzalo, Spurr, Liam F, Li, Yvonne Y, Lamberti, Giuseppe, Venkatraman, Deepti, Umeton, Renato, Cherniack, Andrew D, Nishino, Mizuki, Sholl, Lynette M, Shapiro, Geoffrey I, Awad, Mark M, Cheng, Michael L

“…DNA damage response and repair (DDR) gene alterations are associated with increased tumor-infiltrating lymphocytes, higher genomic instability, and higher…”
Get full text

Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer by Wang, Xinan, Ricciuti, Biagio, Alessi, Joao V, Nguyen, Tom, Awad, Mark M, Lin, Xihong, Johnson, Bruce E, Christiani, David C

“…Despite the therapeutic efficacy of immune checkpoint inhibitors (ICIs) in a subset of patients, consistent and easily obtainable predictors of efficacy remain…”
Get full text

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events by Cortellini, Alessio, Bersanelli, Melissa, Santini, Daniele, Buti, Sebastiano, Tiseo, Marcello, Cannita, Katia, Perrone, Fabiana, Giusti, Raffaele, De Tursi, Michele, Zoratto, Federica, Marconcini, Riccardo, Russano, Marco, Zeppola, Tea, Anesi, Cecilia, Filetti, Marco, Marchetti, Paolo, Botticelli, Andrea, Gelibter, Alain, De Galitiis, Federica, Vitale, Maria Giuseppa, Rastelli, Francesca, Tudini, Marianna, Silva, Rosa Rita, Atzori, Francesco, Chiari, Rita, Ricciuti, Biagio, De Giglio, Andrea, Migliorino, Maria Rita, Mallardo, Domenico, Vanella, Vito, Mosillo, Claudia, Bracarda, Sergio, Rinaldi, Silvia, Berardi, Rossana, Natoli, Clara, Ficorella, Corrado, Porzio, Giampiero, Ascierto, Paolo A.

“…Several studies have found an association between higher body mass index (BMI) and improved clinical outcomes in cancer patients receiving programmed cell…”
Get full text

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable by Cortellini, Alessio, Bersanelli, Melissa, Buti, Sebastiano, Cannita, Katia, Santini, Daniele, Perrone, Fabiana, Giusti, Raffaele, Tiseo, Marcello, Michiara, Maria, Di Marino, Pietro, Tinari, Nicola, De Tursi, Michele, Zoratto, Federica, Veltri, Enzo, Marconcini, Riccardo, Malorgio, Francesco, Russano, Marco, Anesi, Cecilia, Zeppola, Tea, Filetti, Marco, Marchetti, Paolo, Botticelli, Andrea, Antonini Cappellini, Gian Carlo, De Galitiis, Federica, Vitale, Maria Giuseppa, Rastelli, Francesca, Pergolesi, Federica, Berardi, Rossana, Rinaldi, Silvia, Tudini, Marianna, Silva, Rosa Rita, Pireddu, Annagrazia, Atzori, Francesco, Chiari, Rita, Ricciuti, Biagio, De Giglio, Andrea, Iacono, Daniela, Gelibter, Alain, Occhipinti, Mario Alberto, Parisi, Alessandro, Porzio, Giampiero, Fargnoli, Maria Concetta, Ascierto, Paolo Antonio, Ficorella, Corrado, Natoli, Clara

“…Recent evidence suggested a potential correlation between overweight and the efficacy of immune checkpoint inhibitors (ICIs) in cancer patients. We conducted a…”
Get full text

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort by Naqash, Abdul Rafeh, Ricciuti, Biagio, Owen, Dwight H., Florou, Vaia, Toi, Yukihiro, Cherry, Cynthia, Hafiz, Maida, De Giglio, Andrea, Muzaffar, Mavish, Patel, Sandip H., Sugawara, Shunichi, Burkart, Jarred, Park, Wungki, Chiari, Rita, Sugisaka, Jun, Otterson, Gregory A., de Lima Lopes, Gilberto, Walker, Paul R.

“…Background Immune-related adverse events (irAEs) comprise a distinct spectrum of auto-inflammatory manifestations triggered due to immune checkpoint inhibitors…”
Get full text

Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC by Keegan, Alissa, Ricciuti, Biagio, Garden, Padric, Cohen, Limor, Nishihara, Reiko, Adeni, Anika, Paweletz, Cloud, Supplee, Julianna, Jänne, Pasi A, Severgnini, Mariano, Awad, Mark M, Walt, David R

“…BackgroundBlood-based biomarkers of anti-solid tumor immune checkpoint blockade (ICB) response are lacking. We hypothesized that changes in systemic cytokine…”
Get full text

Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC) by Ricciuti, Biagio, Jones, Greg, Severgnini, Mariano, Alessi, Joao V, Recondo, Gonzalo, Lawrence, Marissa, Forshew, Tim, Lydon, Christine, Nishino, Mizuki, Cheng, Michael, Awad, Mark

“…BackgroundCurrently available biomarkers are imperfect in their ability to predict responses to the multiple first-line treatment options available for…”
Get full text

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients by Cortellini, Alessio, Chiari, Rita, Ricciuti, Biagio, Metro, Giulio, Perrone, Fabiana, Tiseo, Marcello, Bersanelli, Melissa, Bordi, Paola, Santini, Daniele, Giusti, Raffaele, Grassadonia, Antonino, Di Marino, Pietro, Tinari, Nicola, De Tursi, Michele, Zoratto, Federica, Veltri, Enzo, Malorgio, Francesco, Garufi, Carlo, Russano, Marco, Anesi, Cecilia, Zeppola, Tea, Filetti, Marco, Marchetti, Paolo, Berardi, Rossana, Rinaldi, Silvia, Tudini, Marianna, Silva, Rosa Rita, Pireddu, Annagrazia, Atzori, Francesco, Iacono, Daniela, Migliorino, Maria Rita, Porzio, Giampiero, Cannita, Katia, Ficorella, Corrado, Buti, Sebastiano

“…Immune-related adverse events (irAEs) developed during immunotherapy with anti-PD-1 agents, could be a predictive surrogate marker of clinical benefit in…”
Get full text

Association between immune-related adverse event timing and treatment outcomes by Hsiehchen, David, Naqash, Abdul Rafeh, Espinoza, Magdalena, Von Itzstein, Mitchell S., Cortellini, Alessio, Ricciuti, Biagio, Owen, Dwight H., Laharwal, Mehak, Toi, Yukihiro, Burke, Michael, Xie, Yang, Gerber, David E.

“…The timing of immune-related adverse events (irAE) associated with immune checkpoint inhibitors (ICI) is highly variable. Although the development of irAE has…”
Get full text

Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers by Cheong, Taek-Chin, Jang, Ahram, Wang, Qi, Leonardi, Giulia C., Ricciuti, Biagio, Alessi, Joao V., Di Federico, Alessandro, Awad, Mark M., Lehtinen, Maria K., Harris, Marian H., Chiarle, Roberto

“…Tyrosine kinase (TK) fusions are frequently found in cancers, either as initiating events or as a mechanism of resistance to targeted therapy. Partner genes…”
Get full text

Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence by Ricciuti, Biagio, Brambilla, Marta, Metro, Giulio, Baglivo, Sara, Matocci, Roberta, Pirro, Matteo, Chiari, Rita

“…In the era of personalized medicine, the identification of targetable genetic alterations represented a major step forward in anticancer therapy. NTRK…”
Get full text

The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks by De Giglio, Andrea, Ricciuti, Biagio, Metro, Giulio

“…This Editorial by De Giglio, Ricciuti and Metro introduces the series :…”
Get full text

Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience by Ricciuti, Biagio, Baglivo, Sara, De Giglio, Andrea, Chiari, Rita

“…Epidermal growth factor receptor (EGFR) gene mutations identify a molecularly defined subset of non-small cell lung cancer (NSCLC) patients who display an…”
Get full text

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC by Alessi, Joao V., Ricciuti, Biagio, Wang, Xinan, Pecci, Federica, Di Federico, Alessandro, Lamberti, Giuseppe, Elkrief, Arielle, Rodig, Scott J., Lebow, Emily S., Eicholz, Jordan E., Thor, Maria, Rimner, Andreas, Schoenfeld, Adam J., Chaft, Jamie E., Johnson, Bruce E., Gomez, Daniel R., Awad, Mark M., Shaverdian, Narek

“…Although concurrent chemoradiation (CRT) and durvalumab consolidation has become a standard treatment for stage III non-small cell lung cancer (NSCLC),…”
Get full text

Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma by Zhang, Tuo, Sun, Beibei, Zhong, Chenxi, Xu, Ke, Wang, Zhexin, Hofman, Paul, Nagano, Tatsuya, Legras, Antoine, Breadner, Daniel, Ricciuti, Biagio, Divisi, Duilio, Schmid, Ralph A., Peng, Ren-Wang, Yang, Haitang, Yao, Feng

Get full text